Evaluating the Evolving Real‐World Adverse Events of <scp>GLP</scp> ‐ <scp>1RAs</scp> Using <scp>FDA</scp> Adverse Event Reporting System ( <scp>FAERS</scp> )
GLP-1RAs are linked to a broad range of AEs across indications. These findings stress the need for careful clinical monitoring and long-term safety evaluation. This study also illustrates how real-world evidence can inform safety communications, as well as hypothesis generation for research on next-generation GLP-1RAs.
Authors
- Mary C. Playdon (ORCID: https://orcid.org/0000-0001-6082-0447)
- David Stone
- Aik Choon Tan
- S. D. Hursting
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- David H. Murdock Research Institute (US)
Publication Details
- Journal
- Obesity
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1002/oby.70176
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 33.63